Osimertinib, a third-generation EGFR-TKI, is not only effective in newly diagnosed EGFR-mutated NSCLC patients, but has also prolonged the PFS and OS of drug-resistant patients with the T790M mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.